Azitra, Inc. cash flow statement
In fiscal 2025, Azitra, Inc.'s operations generated −$11.2m of cash; it spent $24,213 on capital projects, leaving free cash flow of −$11.2m.
Cash flow statement
| Quarter | 2023 Q4Dec 2023 | 2024 Q1Mar 2024 | 2024 Q2Jun 2024 | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | −2,539 | −3,020 | −2,102 | −2,476 | −2,586 | −2,815 | −2,445 | −2,893 |
| Depreciation and amortisation | 32 | 32 | 30 | 30 | 33 | 31 | 31 | 35 |
| Stock-based pay | 35 | 34 | 34 | 144 | 33 | 16 | 4 | 12 |
| Capital spending | 4 | 0 | 0 | 9 | 0 | 12 | 3 | 9 |
| Free cash flow | −2,543 | −3,020 | −2,102 | −2,484 | −2,586 | −2,827 | −2,448 | −2,902 |
| Free cash flow after stock pay | −2,578 | −3,054 | −2,136 | −2,628 | −2,619 | −2,843 | −2,452 | −2,914 |
| Shares issued | — | — | — | 0 | 0 | 694 | 2,848 | 2,400 |
Compare with peers
- Creative Medical Technology Holdings, Inc. cash flow
- Lyell Immunopharma, Inc. cash flow
- AIM Immunotech Inc. cash flow
- Ibio, Inc. cash flow
- Lisata Therapeutics, Inc. cash flow
Head to head: AZTR vs CELZAZTR vs LYELAIM vs AZTR
More: Biotechnology stocks compared, Health Care sector, rankings of US companies